ALTInvestor Events•globenewswire•August 26, 2025 at 11:30 AM

Altimmune to Participate in Upcoming Investor Conferences

Sentiment:Negative (20)

Summary

GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 26, 2025 by globenewswire